Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta is viewed favorably because Ntrust-1/2 enrollment has improved after protocol amendments, with re-dosing, outpatient dosing, reduced monitoring, and broader community access likely to accelerate recruitment. The investment case is further strengthened by the company’s differentiated allogeneic NK-cell platform in autoimmune disease, where NKX019 may deliver rapid B-cell depletion, a deeper immune reset, and lower CRS/ICANS risk than autologous CAR-T. With initial 2026 data expected from both studies and a preliminary YE26 readout framed around 6+ patients at the highest 4B dose with 3+ months follow-up, the setup offers meaningful proof-of-concept and potential de-risking ahead of a more comprehensive FY27 disclosure.

Nkarta is burdened by a sharp 40% jump in 2Q26 operating expenses to $43.1M versus 1Q26, underscoring rising cash burn that outpaced estimates and produced EPS of ($0.54). While the company ended 2Q26 with $243.2M in cash and equivalents, the stated need for roughly $700M in additional financing through 2040 signals substantial dilution and funding risk for a business still dependent on early-stage trials. Its value proposition also looks fragile because all clinical programs remain Phase I or preclinical, the model assigns only 20% probability of success to NKX109 for LN, and there is no guarantee of meaningful efficacy, regulatory success, or competitive differentiation.